Wojcik E G, Van Den Berg M, Poort S R, Bertina R M
Hemostasis and Thrombosis Research Centre, Department of Hematology, University Hospital, Building 1: C2-R, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Biochem J. 1997 May 1;323 ( Pt 3)(Pt 3):629-36. doi: 10.1042/bj3230629.
The propeptide of human coagulation factor IX (FIX) directs the gamma-carboxylation of the first 12 glutamic acid residues of the mature protein into gamma-carboxyglutamic acid (Gla) residues. The propeptide is normally removed before secretion of FIX into the blood. However, mutation of Arg-4 in the propeptide abolishes propeptide cleavage and results in circulating profactor IX in the blood. We studied three such genetic variants, factor IX Boxtel (Arg-4-->Trp), factor IX Bendorf (Arg-4-->Leu) and factor IX Seattle C (Arg-4-->Gln). These variant profactor IX molecules bind normally to anti-FIX:Mg(II) antibodies, which indicates that the mutations do not seriously affect gamma-carboxylation. Metal ion titration of the binding of variant profactor IX to conformation-specific antibodies demonstrates that the calcium-induced conformation is destabilized in the variant molecules. Also the binding of FIX Boxtel to phospholipids and its activation by factor XIa requires a high (>5 mM) calcium concentration. The three-dimensional structure of the Gla domain of FIX in the presence of calcium indicates that the acylation of the amino-terminus, rather than the presence of the propeptide, was responsible for the destabilization of the calcium-induced conformation. In order to confirm this, the alpha-amino group of Tyr1 of FIX was acetylated. This chemically modified FIX showed a similar destabilization of the calcium-induced conformation to variant profactor IX. Our data imply that the amino-terminus of FIX plays an important role in stabilizing the calcium-induced conformation of the Gla domain of FIX. This conformation is important for the binding to phospholipids as well as for the activation by factor XIa. Our results indicate that mutations in FIX that interfere with propeptide cleavage affect the function of the protein mainly by destabilizing the calcium-induced conformation.
人凝血因子IX(FIX)的前肽指导成熟蛋白的前12个谷氨酸残基γ-羧化为γ-羧基谷氨酸(Gla)残基。前肽通常在FIX分泌入血之前被去除。然而,前肽中精氨酸4的突变消除了前肽的切割,导致血液中循环的前因子IX。我们研究了三种这样的基因变体,即因子IX博克斯泰尔(精氨酸4→色氨酸)、因子IX本多夫(精氨酸4→亮氨酸)和因子IX西雅图C(精氨酸4→谷氨酰胺)。这些变体前因子IX分子能正常结合抗FIX:Mg(II)抗体,这表明这些突变不会严重影响γ-羧化。对变体前因子IX与构象特异性抗体结合的金属离子滴定表明,钙诱导的构象在变体分子中不稳定。同样,FIX博克斯泰尔与磷脂的结合及其被因子XIa激活需要高(>5 mM)钙浓度。FIX的Gla结构域在钙存在下的三维结构表明,氨基末端的酰化而非前肽的存在导致了钙诱导构象的不稳定。为了证实这一点,FIX的酪氨酸1的α-氨基被乙酰化。这种化学修饰的FIX在钙诱导构象的不稳定方面表现出与变体前因子IX相似的情况。我们的数据表明,FIX的氨基末端在稳定FIX的Gla结构域的钙诱导构象中起重要作用。这种构象对于与磷脂的结合以及被因子XIa激活都很重要。我们的结果表明,FIX中干扰前肽切割的突变主要通过使钙诱导构象不稳定来影响蛋白质的功能。